The disposition and metabolism of [14C]fluconazole in humans
- PMID: 1680653
The disposition and metabolism of [14C]fluconazole in humans
Abstract
The disposition and metabolism of 14C-labeled fluconazole (100 microCi) was determined in three healthy male subjects after administration of a single oral capsule containing 50 mg of drug. Blood samples, total voided urine, and feces were collected at intervals after dosing for up to 12 days post-dose. Pharmacokinetic analysis of fluconazole concentrations showed a mean plasma half-life of 24.5 hr. Mean apparent plasma clearance and apparent volume of distribution were 0.23 ml/min/kg and 0.5 liter/kg, respectively. There was no evidence of any significant concentrations of metabolites circulating either in plasma or blood cells. Mean total radioactivity excreted in urine and feces represented 91.0 and 2.3%, respectively, of the administered dose. Mean excretion of unchanged drug in urine represented 80% of the administered dose; thus, only 11% was excreted in urine as metabolites. Only two metabolites were present in detectable quantities, a glucuronide conjugate of unchanged fluconazole and a fluconazole N-oxide, which accounted for 6.5 and 2.0% of urinary radioactivity, respectively. No metabolic cleavage products of fluconazole were detected.
Similar articles
-
Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.Drug Metab Dispos. 1996 Feb;24(2):156-63. Drug Metab Dispos. 1996. PMID: 8742226
-
The disposition and metabolic fate of 14C-cibenzoline in man.Drug Metab Dispos. 1986 Jan-Feb;14(1):59-64. Drug Metab Dispos. 1986. PMID: 2868867
-
Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.Drug Metab Dispos. 1997 Jul;25(7):863-72. Drug Metab Dispos. 1997. PMID: 9224781 Clinical Trial.
-
Pharmacokinetics and tissue penetration of fluconazole in humans.Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S318-26. doi: 10.1093/clinids/12.supplement_3.s318. Rev Infect Dis. 1990. PMID: 2184510 Review.
-
The clinical pharmacology of fluconazole.Semin Oncol. 1990 Jun;17(3 Suppl 6):14-8. Semin Oncol. 1990. PMID: 2191442 Review.
Cited by
-
Fluconazole penetration in cerebral parenchyma in humans at steady state.Antimicrob Agents Chemother. 1995 May;39(5):1154-6. doi: 10.1128/AAC.39.5.1154. Antimicrob Agents Chemother. 1995. PMID: 7625804 Free PMC article. Clinical Trial.
-
Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants.CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):500-510. doi: 10.1002/psp4.12414. Epub 2019 May 22. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31087536 Free PMC article.
-
Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?".Antimicrob Agents Chemother. 2021 Jan 20;65(2):e02147-20. doi: 10.1128/AAC.02147-20. Print 2021 Jan 20. Antimicrob Agents Chemother. 2021. PMID: 33168616 Free PMC article. No abstract available.
-
Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO.CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):629-637. doi: 10.1002/psp4.12338. Epub 2018 Aug 13. CPT Pharmacometrics Syst Pharmacol. 2018. PMID: 30033691 Free PMC article.
-
Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes.Br J Clin Pharmacol. 1995 Jul;40(1):83-6. doi: 10.1111/j.1365-2125.1995.tb04540.x. Br J Clin Pharmacol. 1995. PMID: 8527274 Free PMC article.